Nobel Biocare Secures Competitive Advantage

Nobel Biocare Secures Competitive Advantage
June 10, 2005
newratings
1103 GMT [Dow Jones]--Nobel Biocare (NOBE.EB) has secured a strong, long-term competitive advantage by signing the licensing deal with Wyeth (WYE)- to use Wyeth's genetically engineered protein to stimulate bone growth - says Merrill Lynch. Believes that dental implant makers in the future will be able to differentiate their products through improved healing times. If costs permit, the treatment with Wyeth BMP protein along which could become the standard care treatment, and not only for patients with poor bone quality. This "would provide Nobel with an unbeatable proprietary competitive advantage." Keeps at buy. Shares +1.8% at CHF264.50.(SWZ)